Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Genzyme Corp.

(GENZ)

Salomon's Chovav said GENZ is entering a period of slower growth and the stock is fairly valued. According to Chovav, the

Read the full 243 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE